282244
Renal dysfunction could increase serum adiponectin levels among Japanese mala workers
Renal dysfunction could increase serum adiponectin levels among Japanese mala workers
Sunday, November 3, 2013
Objective Increasing adiponectin is a maker of healty lifestyle. However, renal function decline influences adiponectin elevation. We examined the associations of the estimated glomerular filtration rate (eGFR) and proteinuria with serum adiponectin levels among Japanese male workers. Methods The study involved all participants who had undergone measurement of serum adiponectin levels during an annual health examination at a railway company between 2008 and 2012. We analyzed data on serum adiponectin levels, serum creatinine levels, proteinuria, and ages. The eGFR was classified into the following six stages: 90 or greater (G1), 60 to 89 (G2), 45 to 59 (G3a), 30 to 44 (G3b), 15 to 29 (G4), and 15 or less (G5). Proteinuria was classified into the following five stages: -, trace, +, 2+ and 3+. Mean serum adiponectin levels were calculated for each eGFR and proteinuria stages. Results The total number of participants was 17,282. The mean serum adiponectin level among all participants was 7.3±3.6. The mean serum adiponectin levels classified according to the eGFR were 7.4 (G1), 7.2 (G2), 7.8 (G3a), 9.2 (G3b), 11.2 (G4) and 15.3 (G5). Those classified according to the proteinuria reactions were 7.3 (-), 7.1 (trace), 7.1 (+), 8.1 (2+) and 8.6 (3+). These results were showed significant difference with one-way ANOVA (P<0.001). Conclusions Increased serum adiponectin levels were demonstrated in participants in this study. Moreover, the serum adiponectin levels have higher at advanced stages of eGFR or larger amounts of proteinuria. It is necessary to consider the renal function when evaluating adiponectin.
Learning Areas:
EpidemiologyOccupational health and safety
Learning Objectives:
Explain serum adiponectin levels with renal function decline.
Keywords: Occupational Health, Epidemiology
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: There is no conflict of interest in our study.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
Back to: 2073.0: Poster Session: Chemicals and Toxic Substances